Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: J Hepatol. 2010 Dec 13;55(2):289–298. doi: 10.1016/j.jhep.2010.11.019

Figure 1. IL28B inhibits HCV replication in OR6 cells and JFH1 infection model.

Figure 1

Figure 1

(A) OR6 cells were incubated with different doses of IL28B or 30 IU/ml IFNα as indicated for 24 hours. Renilla luciferase activity and cellular ATP levels were measured. (B) OR6 cells were incubated with 100 ng/ml IL28B for different times as indicated. Renilla luciferase activity and cellular ATP levels were measured. (C) OR6 cells were incubated with 100 ng/ml IL28B for different times as indicated. Cell lysates were analyzed by immunoblotting with the indicated antibodies (D) OR6 cells were incubated with different doses of IFNα, IL28A, IL28B or IL29 as indicated for 48 hours. Renilla luciferase activity and cellular ATP levels were measured. (E) OR6 cells were incubated with 100 ng/ml IL28A, IL28B, IL29 or 30IU/ml IFNα for different times as indicated. Renilla luciferase activity and cellular ATP levels were measured. (F) JFH1-infected Huh7.5.1 cells were incubated with different doses of IL28B or IFNα as indicated for 24 hours. Total RNA was isolated and reversely transcribed and then quantitive PCR was performed. (G) JFH1-infected Huh7.5.1 cells were incubated with 100 ng/ml IL28B for different times as indicated. Total RNA was isolated and reversely transcribed and then quantitive PCR was performed. (H) JFH1-infected Huh7.5.1 cells were incubated with 100 ng/ml IL28B for different times as indicated. Cell lysates were analyzed by immunoblotting with the indicated antibodies.